Relay Therapeutics

Update in progress

RLAY (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming small molecule discovery for targeted oncology and genetic diseases. Its lead programs include RLY-2608, a pan-mutant, isoform-selective PI3K alpha inhibitor in trials for breast cancer and solid tumors; aGal chaperone for Fabry disease; RLY-8161, a RAS-family oncogene driver; and lirafugratinib (RLY-4008), a receptor tyrosine kinase inhibitor. It collaborates with D. E. Shaw Research, Elevar Therapeutics, and Pfizer.

Company score

Sentiment: 0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.24; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.08; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.24; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive